About Britannia Pharmaceuticals
We continue to redefine and innovate drug delivery methods for Parkinson’s and other disorders, and are committed to combining research and development excellence with world-class patient care, through caring for peoples health as a trusted partner. Britannia puts its people at the heart of everything we do and ensures that our values and behaviours are lived every day. Britannia grew a lot the last few years and will continue to do so into new markets which makes it an exciting time to join the company! VASILIKI PAPACHRISTOPOULOU, INTERNATIONAL PRODUCT MANAGER For more than 30 years, our primary field of interest has been the development of innovative, patient-centric technology that effectively delivers therapies to patients with Parkinson’s disease. We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes and improve quality of life. Britannia Pharmaceuticals Ltd. has undergone a large growth in the past 30 years, and operates as the global specialty centre for Parkinson’s Disease in the STADA Network. Read about journey from a small, family run business, to sharing products internationally.
Key Details
Profiles
Please note, this profile is not managed by Britannia Pharmaceuticals. The information on this profile may have been submitted by an independent community member or obtained from a public source. As a result, it may be outdated or inaccurate. Logo provided by Clearbit to help identify the profile for review purposes. Cademy is an unbiased information source and does not have any affiliation with or directly endorse this profile.
Primary Location
- 200 Longwater Avenue, Green Park
- Reading
- United Kingdom
- RG2 6GP
All Locations
- 200 Longwater Avenue, Green Park, Reading